Efficacy and Safety of Proxalutamide in Severe or Critically Ill COVID-19 Patients: Study Protocol for an Exploratory Trial

    June 2023 in “ BMC Pharmacology and Toxicology ”
    Chunxue Bai, Minghe Ju, Hao Wang … Jun Fan
    Studysummary This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on bmcpharmacoltoxicol.biomedcentral.com →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide medRxiv (Cold Spring Harbor Laboratory) · 2021
    2. Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial medRxiv (Cold Spring Harbor Laboratory) · 2021
    3. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial Cureus · 2021
    4. Alopecia and Grey Hair Are Associated with COVID-19 Severity Experimental Dermatology · 2020
    5. The Role of Androgens in COVID-19 Diabetes and Metabolic Syndrome: Clinical Research and Reviews · 2020
    6. Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign Journal of The American Academy of Dermatology · 2020
    7. Male Balding Is a Major Risk Factor for Severe COVID-19 Journal of The American Academy of Dermatology · 2020